Riding the new wave of pharma market trends dk

3,226 views
2,815 views

Published on

Published in: Business, Economy & Finance
2 Comments
5 Likes
Statistics
Notes
No Downloads
Views
Total views
3,226
On SlideShare
0
From Embeds
0
Number of Embeds
27
Actions
Shares
0
Downloads
268
Comments
2
Likes
5
Embeds 0
No embeds

No notes for slide
  • Indonesia Pharma market has reached OKU YEN 4.7 or equal to IDR 49 Trillion in 2013 MAT2013Q2. The market in 2013 was driven by Ethical Market. The composition between Ethical Vs OTC was 40% for OTC and 60% for Ethical in 2013. However, in the next 5 years, OTC is expected to drive the market, since there will be many changes in the pharma structure, due to the implementation of NHI (National Health Insurance) starting 2014. . And forecasted to reachIndonesia Pharma is a growth story, and story still continues until the next 5 years – according to the forecastIs like a beach wave! And it’s getting higher.
  • Among the other countries in the South Asia Region, Indonesia is very attractive. The 3rd largest market. In the next 5 years we can exceed Australia, to be 2nd largest after India.
  • Vs other industry CAGR: Cigarette, Hospital, Clinics, FMCG, Bottled water Let’s see the comparison of Pharma Industry comparing to the other industry. How attractive this Pharma Industry
  • Top 20 CorporationsTotal companies in Indonesia Pharmaceutical market reach 232 companies, which implies that the market structure tends to be perfect competition – with the top 20 companies only occupying 67% of market shareThe market is dominated by local companies which produce many generic products as their main business portfolio. LAPI has the biggest growth in 2013Q2 with +33% growth.TAKEDA ranks at #24 among total corporations and #9 among MNC.Many of local companies are still driven by 1stOwners Generation (Family business)Who’s riding the wave?
  • Based on our own market category definition, Lifestyle Product (incl Multi Vitamin and Tonic) is the leading category is at 18.8% of share with +3.8% growth. The other Top category are Herbal and Skin Vitamin which driving the market growth.
  • Are you ready for the next Wave?Indonesia Pharma is a growth story, and story still continues until the next 5 years – according to the forecastIs like a beach wave! And it’s getting higher.
  • Riding the new wave of pharma market trends dk

    1. 1. Riding the new wave of Pharma Market Trends
    2. 2. Content
    3. 3. Indonesia Pharma Market Sales Value 2009-2013 & Forecast 2017 7,493 OKU YEN Sales Value MAT 2013Q2 43% 4,710 OTC 3,005 40% 57% ETHICAL 42% TOTAL MARKET IMS ITMA MAT2013Q2 60% 58% 2009 2013 F-2017
    4. 4. Pharma Market Size – South Asia Region EUR 30.3 BIO, YoY +5.5% +20.6% +6.2% +5.7% -1.6% +3.6% +8.7% +12% +9.7% TAKEDA SA Region Report MAT2013Q2
    5. 5. Domestic Growth Comparison +20% Motor Vehicle +20% Tobacco +7% Coal ID Economy +6% +6% Pharma +12% Textile +2% Electronic F&B +2% -5% BPS Added Value 2010 Clothing
    6. 6. Pharma Market Forecast Drivers • Key positive (+) forecast drivers: – Implementation of a National Health Insurance (NHI) system – Expansion and improvement of the healthcare infrastructure – Expansion of the private hospital sector • Key negative (-) forecast drivers: – Encouragement of generic usage and growing pressure on prices following implementation of the NHI system – Demographic factors as population growth slows IMS Prognosis MAT 2013Q2
    7. 7. CAGR 5yrs Therapeutic Areas Growth 25% L ANTINEOPLAST+IMMUNOM ODUL, 2%, 18% V VARIOUS, 4%, 19% 20% M MUSCULO-SKELETAL SYSTEM, 6%, 18% C CARDIOVASCULAR SYSTEM, 10%, 15% 15% B BLOOD + B.FORMING ORGANS, 3%, 16% D DERMATOLOGICALS, 5%, 15% N NERVOUS SYSTEM, 11%, 12% Pharma CAGR +12% 10% R RESPIRATORY SYSTEM, 9%, 10% 5% J SYSTEMIC ANTIINFECTIVES, 15%, 9% A ALIMENTARY T.& METABOLISM, 24%, 9% 0% 0% 5% 10% 15% 20% 25% Market Share IMS Prognosis MAT 2013Q2 30%
    8. 8. Therapeutic Areas Growth - Ethical CAGR 5yrs 25% K HOSPITAL SOLUTIONS, 4%, 17% 20% A ALIMENTARY T.& METABOLISM, 9%, 15% 15% Pharma CAGR +12% C CARDIOVASCULAR SYSTEM, 8%, 15% R RESPIRATORY SYSTEM, 3%, 13% 10% N NERVOUS SYSTEM, 6%, 11% 5% J SYSTEMIC ANTIINFECTIVES, 15%, 9% 0% 0% 5% 10% 15% 20% Market Share IMS Prognosis MAT 2013Q2
    9. 9. CAGR 5yrs Therapeutic Areas Growth - OTC 30% 25% M MUSCULO-SKELETAL SYSTEM, 2%, 22% V VARIOUS, 4%, 19% 20% D DERMATOLOGICALS, 4%, 19% 15% Pharma CAGR +12% N NERVOUS SYSTEM, 5%, 12% 10% 5% R RESPIRATORY SYSTEM, 6%, 8% A ALIMENTARY T.& METABOLISM, 15%, 6% 0% 0% 5% 10% 15% 20% Market Share IMS Prognosis MAT 2013Q2
    10. 10. Top 25 TC Level 3 IMS QPMU 2013Q2
    11. 11. Top Corporations Sales Trade Value Rank 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Top 20 Corporations IND TOTAL MARKET KALBE GROUP SANBE SOHO GROUP DEXA MEDICA GROUP PHAROS GROUP TEMPO GROUP NOVARTIS GROUP GLAXOSMITHKL GROUP FAHRENHEIT SANOFI-AVENTIS GRP DARYA-VARIA GROUP KONIMEX BAYER INDONESIA MENSA GROUP KIMIA FARMA GROUP NOVELL PHARM PFIZER GROUP LAPI INTERBAT INDOFARMA B.INGELHEIM GROUP MERCK INDONESIA GP J&J IMS ITMA MAT 2013Q2 Status LOCAL LOCAL LOCAL LOCAL LOCAL LOCAL MNC MNC LOCAL MNC LOCAL LOCAL MNC LOCAL LOCAL LOCAL MNC LOCAL LOCAL LOCAL MNC MNC MNC 2009 3,005 439 208 167 175 93 146 75 86 71 78 81 60 94 89 70 53 88 32 70 56 44 55 44 Market Share CAGR 5yrs 2013 2009 2013 2013 4,710 647 326 278 272 207 200 145 135 130 126 118 116 113 112 105 103 101 100 94 87 81 76 68 100% 13% 6% 5% 5% 3% 4% 2% 3% 2% 2% 2% 2% 3% 3% 2% 2% 3% 1% 2% 2% 1% 2% 1% 100% 12% 6% 5% 5% 4% 4% 3% 3% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 1% 1% 12% 10% 12% 14% 12% 22% 8% 18% 12% 16% 13% 10% 18% 5% 6% 11% 18% 4% 33% 8% 12% 16% 9% 12% 66% +12
    12. 12. Top Corporations - Ethical Sales Trade Rank Top 20 Corporations in OTC Growth CAGR 5yrs 2013 2013 2013 2013 3,177 Status Market Share 100% 11% 13% 1 KALBE GROUP LOCAL 445 14% 17% 15% 2 SANBE LOCAL 281 9% 16% 15% 3 DEXA MEDICA GROUP LOCAL 202 6% 16% 12% 4 NOVARTIS GROUP MNC 134 4% 10% 20% 5 SANOFI-AVENTIS GRP MNC 126 4% 8% 13% 6 FAHRENHEIT LOCAL 119 4% 17% 17% 7 PFIZER GROUP MNC 101 3% -1% 4% 8 KIMIA FARMA GROUP LOCAL 81 3% -4% 11% 9 MENSA GROUP LOCAL 80 3% 11% 13% 10 INDOFARMA LOCAL 77 2% 16% 11% 11 GLAXOSMITHKL GRP MNC 74 2% 16% 10% 12 BAYER INDONESIA MNC 67 2% 5% 9% 13 SOHO GROUP LOCAL 58 2% -3% 14% 14 OTSUKA GROUP LOCAL 57 2% 16% 9% 15 ACTAVIS MNC 56 2% 23% 28% 16 INTERBAT LOCAL 56 2% 9% 7% 17 DARYA-VARIA GROUP LOCAL 55 2% 7% 11% 18 B.INGELHEIM GROUP MNC 53 2% 20% 20% 19 PHAROS GROUP LOCAL 53 2% 5% 14% 20 ASTRAZENECA MNC 47 1% 12% 9% IMS ITMA MAT 2013Q2
    13. 13. Top Corporations - OTC Sales Trade Rank Top 20 Corporations in OTC Growth CAGR 5yrs 2013 2013 2013 2013 2,134 Status Market Share 100% 15% 11% 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 SOHO GROUP KALBE GROUP TEMPO GROUP PHAROS GROUP KONIMEX DEXA MEDICA GROUP DARYA-VARIA GROUP GLAXOSMITHKL GRP LAPI NOVELL PHARM BAYER INDONESIA SANBE INTERBAT J&J MERCK INDONESIA GP MENSA GROUP COMBIPHAR GROUP B.INGELHEIM GROUP LOCAL LOCAL LOCAL LOCAL LOCAL LOCAL LOCAL MNC LOCAL LOCAL MNC LOCAL LOCAL MNC MNC LOCAL LOCAL MNC 219 202 179 154 116 70 63 61 60 58 46 45 38 35 34 32 31 27 10% 9% 8% 7% 5% 3% 3% 3% 3% 3% 2% 2% 2% 2% 2% 1% 1% 1% 25% -2% 6% 34% 11% 10% 17% 8% 79% 30% 19% 7% 6% -1% 7% -11% -3% 12% 13% 2% 8% 26% 18% 11% 8% 14% 55% 17% 0% -2% 8% 9% 6% -6% 7% 10% 19 MAHAKAM BETA FARMA LOCAL 27 1% 68% 45% 20 21 22 HISAMITSU PHARMA KIMIA FARMA GROUP TAISHO GROUP MNC LOCAL LOCAL 26 24 24 1% 1% 1% 38% 9% 4% 26% 9% 12% IMS ITMA MAT 2013Q2
    14. 14. Top Products Sales Value Market CAGR 2013 Share 5Yrs Sales Value Market 2013 Share TOP 20 OTC PRODUCTS PROMAG KLB NOURISH SKIN P-I IMBOOST SHO PARAMEX KOX BODREX TFC OMEPROS P-I NEO-RHEUMACYL TFC SALONPAS MEDICATED HSM HEMAVITON JRENG TFC BETADINE MKB CALCIUM-D-REDOXON B/S THROMBOPHOB NMK MIXAGRIP DKS ASTHIN SHO SUPER ESTER C TCN PRORIS P-I VIOSTIN DS P-I NEUROBION MCK COUNTERPAIN TIP MICROLAX P-I IMS ITMA MAT 2013Q2 CAGR 5Yrs TOP 20 ETHICAL PRODUCTS 51.5 49.2 40.1 38.4 33.9 22.5 21.2 20.8 19.9 19.7 19.4 19.0 18.7 18.5 17.9 16.5 16.2 16.2 15.3 14.5 2% 2% 2% 2% 2% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 11% 14% 19% 18% 9% 110% 6% 24% -4% 47% 0% 10% 8% 14% 7% 35% 73% 8% 13% 27% 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 DIOVAN NVR SUPER TETRA D.V LIPITOR PFZ PLAVIX S.A SOMADRIL COMP ATV TERFACEF SN5 AMOXSAN SN5 MICARDIS B.I NORVASK PFZ CEFAT SN5 PANTOZOL NYE VENTOLIN GSK PLASBUMIN DPI CEFSPAN KLB CATAFLAM NVR RINGER LAKTAT(OGB) WIB NOVORAPID N-N PONSTAN PFZ NOVOMIX 30 N-N SPORETIK SN5 29.1 21.4 20.2 18.5 18.0 16.3 15.5 15.0 14.6 14.4 14.1 14.0 14.0 13.3 12.9 12.9 12.8 12.8 12.2 11.9 1% 1% 1% 1% 1% 1% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 48% 9% 9% 13% 41% 14% 8% 62% -3% 7% 14% 19% 26% 11% 29% 14% 90% 0% 56% 20%
    15. 15. Top 20 Products Over 3 MATs IMS QPMU 2013Q2
    16. 16. OTC Trends MAT 2013Q2 $ Share (%) 2,000.0 1,800.0 1,600.0 Lifestyle 19% OTC Nutrition 1,400.0 1,200.0 1,892.0 1,000.0 800.0 600.0 1,260.2 400.0 200.0 0.0 114.2 45.2 2009 MAT 2013Q2 OTC + Nutrition Lifestyle Herbal Digestive / GI Skin Vitamin Respi Laxative Memory Others Sales in OKU YEN Share (%) CAGR 2009 MAT 2013 Q2 2009 MAT 2013 Q2 09-'13 1,340.2 1,885.0 100.0% 100.0% 8.9% 339.4 363.9 24.7% 18.8% 1.8% 109.6 215.8 8.0% 11.1% 18.5% 47.6 70.4 3.5% 3.6% 10.3% 42.9 101.5 3.1% 5.2% 24.0% 34.2 52.3 2.5% 2.7% 11.2% 33.2 51.7 2.4% 2.7% 11.7% 6.0 17.5 0.4% 0.9% 30.9% 761.5 1,064.1 55.4% 54.9% 8.7% Skin Vitamin 5% Digestive / GI 4% Laxative 3% Herbal Memory 11% 1%
    17. 17. Business Partnership Formats Format Postive (+) Negative (-) Case Study In-sourcing / Contract Sales Force Co-partner is carrying and marketing Host-Partner products by commision based • Full authority of marketing and promotion of the products • No subject to production and COGS • No subject to distribution margin (depends on MoU) • Most of outsourced products are unpromoted which in mature/ declining growth • To be ready for additional reporting system • Subject to product management fee • Ethica to MSD, for unpromoted products • Dexa to Novartis, for unpromoted products • InMark to Takeda, for established (legacy) products • Abbot to GSK, for established & unpromoted products Co-Marketing & Co-Promotion both Host-partner and Co-partner are promoting the products but divided into agreed market segments (geographical, specialty, outlets type, etc) • Partnership and gain support from one to another • Clear market segmentation • Clear marketing promotion & message • Promotion startegy is controlled by partner company (CoC, reporting, markets) • Dependent to the market segmentation • Dependent to distribution coverage • In-mark/Dexa and Pfizer, for Norvask • In-mark/Dexa and Novartis, for Diovan Bulk Purchasing Co-partner purchases the products at discounted price and then selling it using their own sales model • Full control and authority for products management & marketing • No market segmentation • Huge risk of low sales  required strong marketing investment • Distribution hassle • Pharos to Nycomed, for Albothyl 2nd Brand Co-Partner manufactures a generic of host-partner’s product • Full control and authority for products management & marketing • Market is already shaped • Follower advantage to original brand • Complex segmentation • Cannibalism • Confrontation in field force level • Dexa with Pfizer, for Norvask and Tensivask
    18. 18. Pharma Business Deals News Update • PT. Soho Farmasi (51%) joint venture with Frenesius Kabi (49%) to establish a new business entity, including Generics Factory • PT Kalbe Farma Tbk (KLBF) and PT Indofarma Tbk (INAF) plans to conduct acquisitions this year • PT Indofarma Tbk (INAF), strengthens its strategic alliance with PT Sysmex Indonesia, a Japan-based clinical laboratory • PT Indofarma Tbk will invest 263 billion dollars for the development of their drug manufacturing capacity, ahead of the implementation of the national social security system of the early 2014. • PT B Braun Indonesia develops IV fluid factory in Indonesia
    19. 19. Indonesia Pharma Market Sales Value 2009-2013 & Forecast 2017 7,493 OKU YEN Sales Value MAT 2013Q2 43% 4,710 OTC 3,005 40% 57% ETHICAL 42% TOTAL MARKET IMS ITMA MAT2013Q2 60% 58% 2009 2013 F-2017
    20. 20. THANK YOU

    ×